Cellectis SA ( (CMVLF) ) has released its Q2 earnings. Here is a breakdown of the information Cellectis SA presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cellectis S.A. is a clinical-stage biotechnology company that specializes in developing cell and gene therapies using its pioneering gene-editing platform, with a focus on allogeneic CAR T immunotherapies for oncology. The company operates in the biotechnology sector and is known for its end-to-end control of the cell and gene therapy value chain.
In its second-quarter 2025 earnings report, Cellectis highlighted several key developments, including the completion of end-of-Phase 1 meetings with the FDA and EMA for its lasme-cel (UCART22) program in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and the ongoing Phase 1 study for eti-cel (UCART20x22) in non-Hodgkin lymphoma. The company also announced an upcoming Investor R&D Day in New York City and the appointment of André Muller to its Board of Directors.
Financially, Cellectis reported consolidated revenues and other income of $30.2 million for the first half of 2025, a significant increase from $16.0 million in the same period in 2024, primarily due to progress in its AstraZeneca collaboration. However, the company recorded a net loss of $41.9 million, attributed to a $36.1 million swing from a net financial gain in the previous year to a net financial loss in 2025, largely due to foreign exchange losses.
Cellectis maintains a strong cash position with $230 million in cash, cash equivalents, and fixed-term deposits as of June 30, 2025, which is expected to support operations into the second half of 2027. The company plans to focus its financial resources on advancing its pipeline, including the pivotal Phase 2 trial for lasme-cel and ongoing R&D activities in partnership with AstraZeneca.
Looking ahead, Cellectis remains committed to progressing its clinical programs and leveraging its gene-editing platform to address unmet medical needs in oncology. The company anticipates further developments in its pipeline and collaborations, which could potentially enhance its financial performance in the coming years.